Pringgodigdo Nugroho

Dr. Pringgodigdo Nugroho

Department of Internal Medicine Faculty of Medicine Universitas Indonesia – dr. Cipto Mangunkusumo Hospital
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Annals of Medicine
Verified
Journal Article
Open access
PNPringgodigdo Nugroho
Pringgodigdo Nugroho
HAHubert Andrew
Hubert Andrew
KKKelvin Kohar
Kelvin Kohar
CNChairina Azkya Noor
Chairina Azkya Noor
ASAida Lydia Sutranto
Aida Lydia Sutranto
The global burden of hypertension remains an unsolved problem, especially in low- and middle-income countries (LMICs). For this reason, clinical practice guidelines containing the latest evidence-based recommendations are crucial in the management of hypertension. It is noteworthy that guidelines simply translated from those of high-income countries (HICs) are not the solution to the problem of hypertension in LMICs. Among the numerous guidelines available, those of the World Health Organisation and the International Society of Hypertension are the latest to be published as of the writing of this article. In this review, we conducted both general and specific comparisons between the recommendations supplied by both guidelines. Differences in aspects of hypertension management such as the timing of antihypertensive initiation, assessment of comorbidities and cardiovascular risk factors, pharmacological therapy selection, and blood pressure target and reassessment are explored. Lastly, the implications of the differences found between the two guidelines in both LMICs and HICs are discussed.

1 January 2024 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
PNPringgodigdo Nugroho
Pringgodigdo Nugroho
TSTri Hadi Susanto
Tri Hadi Susanto
MBMaruhum Bonar
Maruhum Bonar
ARAulia Rizka
Aulia Rizka
ALAida Lydia
Aida Lydia
FHFidel Hermanto
Fidel Hermanto
Background: Diabetic kidney disease (DKD) is the most common and deranging microvascular complication of diabetes mellitus (DM). Podocytopathy is a key component of glomerular damage in DKD. Micro RNA-21 (miRNA-21) is an epigenetic regulator that plays a role in podocyte damage; however, the results of previous studies have not resolved the controversy about the role of miRNA-21 in the pathogenesis of DKD. Objective: The objective was to investigate the correlation between miRNA-21 levels and urinary nephrin, podocin, and urinary albumin-creatinine ratio (UACR) in patients with type 2 DM and albuminuria. Design: This is a cross-sectional study. Setting: This study was carried out in internal medicine outpatient clinic of Cipto Mangunkusumo Hospital Jakarta, Indonesia. Patients: This study consisted of 42 adults with type 2 DM and albuminuria. Measurements: The measurements include (1) Serum miRNA-21; (2) urinary podocin, nephrin, and albumin-creatinine ratio; and (3) serum miRNA-21 correlated to urinary podocin, nephrin, and albumin-creatinine ratio. Methods: The Spearman bivariate analysis to assess the correlation of miRNA-21 with nephrin, podocin, and UACR. Results: The mean relative expression of miRNA-21 was 0.069 (0.024), the median for nephrin, podocin, and UACR was 35.5 (15.75-51.25) ng/mL, 0.516 (0.442-0.545) ng/mL, and 150 (94.56-335.75) ng/mL, respectively. A correlation between miRNA-21 and nephrin was observed (r = 0.598; P < .0001). There was a correlation between miRNA-21 and UACR (r = 0.604; P < .0001). No correlation was found between miRNA-21 and podocin. Limitations: A lack of non-DM and non-albuminuric control population and small sample size. We could not exclude concurrent disease, and all other potential confounding variables, particularly those related to inflammation. Conclusions: The miRNA-21 can be considered an early biomarker for podocytopathy and albuminuria in DM, highlighting its potential for early diagnostic and therapeutic interventions. Further research is required to confirm these findings and explore their clinical applications, which could significantly alter management strategies for DKD.

27 October 2025 in Annals of Medicine
Verified
Journal Article
Open access
PNPringgodigdo Nugroho
Pringgodigdo Nugroho
ALAida Lydia
Aida Lydia
PSPradana Soewondo
Pradana Soewondo
ITIna Susianti Timan
Ina Susianti Timan
KHKuntjoro Harimurti
Kuntjoro Harimurti
ZAZulkhair Ali
Zulkhair Ali
Diabetic kidney disease (DKD) is marked by inflammation, fibrosis and oxidative stress. Calcitriol may offer renoprotective effects by modulating these processes. This double-blind, randomized controlled trial investigated the effects of calcitriol supplementation on kidney injury biomarkers in patients with early DKD. This study randomized 120 patients with controlled type 2 diabetes, albuminuria, and estimated glomerular filtration rate above 45 mL/min/1.73 m2 to receive either 0.25 mcg/d calcitriol or a placebo for six months. The primary outcomes were changes in urinary nephrin, podocin, kidney injury molecule-1 (KIM-1), interleukin-6 (IL-6), and urinary albumin-to-creatinine ratio (UACR). After 6 months, the calcitriol group showed lower increases in IL-6 levels (baseline 0.72 pg/mL to 0.87 pg/mL) compared to placebo (1.03 pg/mL to 2.94 pg/mL, p = 0.006), and lower KIM-1 levels (0.36 to 0.51 ng/mL vs. 0.55 to 0.99 ng/mL, p = 0.020). Full baseline and post-treatment values are provided in Tables 2. Urinary nephrin levels decreased in the calcitriol group, while change in the placebo group varied. Although UACR decreased more in the calcitriol group, the difference was not statistically significant (p = 0.099). Positive correlations were observed between KIM-1 and IL-6 in both groups, and a moderate correlation between IL-6 and urinary nephrin was observed in in the calcitriol group. No significant adverse events or changes in serum calcium or phosphate levels were reported. These findings suggest that Calcitriol supplementation may provide renoprotection in patients with early DKD by reducing inflammation and tubular injury, with potential effects on podocyte injury. Further research is required to validate these effects and determine the optimal dosing regimens. ClinicalTrials.gov (NCT05298163).

1 November 2025 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Open access
PDF file
PNPringgodigdo Nugroho
Pringgodigdo Nugroho
Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2D), which often leads to diabetic kidney disease (DKD). Traditional therapies, including renin- angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors, are effective in slowing CKD progression. However, these approaches are insufficient to comprehensively inhibit mineralocorticoid receptor (MR) overactivation in the kidneys, which remains a significant driver of inflammation, fibrosis, and oxidative stress. These pathological processes accelerate kidney damage and cardiovascular complications. Finerenone-a nonsteroidal mineralocorticoid receptor antagonist-represents a new frontier in renal protection. Unlike steroidal mineralocorticoid antagonists (MRAs), finerenone offers a more selective MR blockade, reducing kidney inflammation and fibrosis without significantly raising serum potassium levels. Landmark trials have demonstrated the ability of finerenone to significantly reduce kidney and cardiovascular events in patients with T2D and CKD. Clinical evidence has highlighted finerenone as an effective option for slowing DKD progression while maintaining a favorable safety profile. Based on these findings, recent guidelines have incorporated finerenone as a recommended therapy for patients with T2D and CKD, emphasizing its role in reducing both renal and cardiovascular risks. This review provides a comprehensive overview of the available data to offer a deeper understanding of the potential of finerenone to transform CKD management for T2D patients.

1 October 2024 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
PDF file
PNPringgodigdo Nugroho
Pringgodigdo Nugroho
RSRiahdo Juliarman Saragih
Riahdo Juliarman Saragih
ALAida Lydia
Aida Lydia
MMMuhadi Muhadi
Muhadi Muhadi
HIHarry Isbagio
Harry Isbagio
FHFidel Hermanto
Fidel Hermanto
Background: Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease, and podocytopathy is an early manifestation of DKD characterized by the urinary excretion of podocyte-specific proteins, such as nephrin and podocin. Asymmetric dimethylarginine (ADMA)—a biomarker of endothelial dysfunction—is associated with progressive kidney dysfunction. However, the mechanism of endothelial dysfunction in DKD progression is unclear. The aim of this study was to investigate the correlations of ADMA levels with nephrin, podocin, and the podocin:nephrin ratio (PNR) in DKD patients. Methods: A cross-sectional study of 41 DKD outpatients was performed in two hospitals in Jakarta from April–June 2023. The collected data included the subjects’ characteristics, histories of disease and medication, and relevant laboratory data. Serum ADMA was measured using liquid chromatography, while urinary podocin and nephrin were measured using the enzyme-linked immunosorbent assay (ELISA) method. A correlation analysis was performed to evaluate the correlation of ADMA with nephrin, podocin, and PNR. Regression analysis was performed to determine confounding factors. Results: The mean value of ADMA was 70.2 (SD 17.2) ng/mL, the median for nephrin was 65 (20– 283 ng/mL), and the median of podocin was 0.505 (0.433– 0.622) ng/mL. ADMA correlated significantly with nephrin (r = 0.353, p = 0.024) and PNR (r = − 0.360, p = 0.021), but no correlation was found between ADMA and podocin (r = 0.133, p = 0.409). The multivariate analysis showed that body mass index was a confounding factor. Conclusion: This study revealed weak positive correlations between ADMA and urinary nephrin and between ADMA and PNR. No correlation was found between ADMA and urinary podocin.

30 June 2020 in Jurnal Penyakit Dalam Indonesia
Verified
Journal Article
Open access
PDF file
ALAida Lydia
Aida Lydia
GRGrecia Rachmaningrum
Grecia Rachmaningrum
HSHamzah - Shatri
Hamzah - Shatri
PNPringgodigdo Nugroho
Pringgodigdo Nugroho
Pendahuluan. Rujukan yang tepat waktu kepada dokter spesialis konsultan ginjal pada pasien penyakit ginjal kronik (PGK) sangat penting. Rujukan terlambat pada pasien PGK meningkatkan angka morbiditas dan mortalitas. Sebagai rumah sakit rujukan tersier dimana semua pasien dilayani oleh konsultan (sub-spesialis), RSUPN. Dr. Cipto Mangunkusumo (RSCM) belum mempunyai data mengenai rujukan terlambat pasien PGK. Penelitian ini bertujuan untuk mengetahui proporsi rujukan terlambat pasien PGK-stadium akhir yang menjalani hemodialisis pertama kali di RSCM dan faktor-faktor yang berhubungan. Metode. Dilakukan studi potong lintang terhadap pasien PGK-stadium akhir yang menjalani hemodialisis pertama kali di RSCM dari April 2017 hingga Januari 2019. Rujukan terlambat didefinisikan sebagai waktu yang dibutuhkan subjek mendapatkan perawatan pra-dialisis oleh dokter spesialis konsultan ginjal lebih dari 6 bulan. Variabel tidak tergantung terdiri dari usia, jenis kelamin, tingkat pendidikan, tingkat penghasilan, tingkat kemandirian, risiko penyakit komorbid, kepatuhan berobat dan etiologi PGK. Dari data register hemodialisis dan rekam medik dilakukan penelusuran subjek yang menjalani hemodialisis pertama kali di RSCM. Subjek hidup diberikan informed consent untuk dilakukan wawancara. Sementara pada subjek meninggal dan yang tidak dapat dihubungi, data didapatkan dari rekam medik. Analisis bivariat dilakukan menggunakan uji Chi-square, bila persyaratan tidak terpenuhi maka menggunakan uji Fisher. Variabel-variabel yang bermakna selanjutnya dianalisis dengan uji regresi logistik. Hasil. Dari 210 subjek pasien PGK-stadium akhir yang menjalani hemodialisis pertama kali di RSCM, didapatkan 189 pasien dirujuk terlambat (proporsi 90%; IK 95% 86,2-96,7). Berdasarkan hasil analisis multivariat, dua faktor utama yang berhubungan dengan rujukan terlambat adalah tingkat kemandirian rendah (p=0,002; OR 6,71; IK 95% 2,02-22,32) dan ketidak-patuhan berobat (p=0,001; OR 7,42; IK 95% 2,33-23,62). Simpulan. Proporsi rujukan terlambat pasien PGK di RSCM masih sangat tinggi (90%). Tingkat kemandirian rendah dan ketidak-patuhan berobat berhubungan dengan kejadian keterlambatan rujukan pasien PGK di RSCM. Diperlukan studi lebih lanjut untuk mengetahui peranan faktor lainnya seperti sistem rujukan kesehatan yang berlaku dan implementasinya oleh dokter di lapangan. Kata Kunci: Penyakit ginjal kronik stadium akhir, rujukan terlambat,  terapi pengganti ginjal
Factors Associated with Late Referral in End Stage Renal Disease Patients at Dr. RSUPN Cipto Mangunkusumo Introduction. Timely referral to nephrologist is important in Chronic Kidney Disease (CKD) patients. Late referral has been proven increasing the morbidity and mortality rate. Factors affecting late referral are well known in western population. As a tertiary referral hospital where all patients are served by consultants, Dr. Cipto Mangunkusumo General Hospital (RSCM) do not have data regarding late referral of CKD patients. This study aimed to determine the proportion of late referral to nephrologist of CKD-End Stage Renal Disease (ESRD) patients in RSCM and its related factors. Methods. A cross-sectional study of 210 CKD-ESRD patients who started dialysis initiation in dialysis unit of Cipto Mangunkusumo General Hospital from April 2017 to January 2019. Late referral were defined as patients who were referred to nephrologist more than 6 months prior to dialysis. Independent variables consist of age, gender, education, income status, ambulation status, risk of comorbid disease, compliance and underlying of kidney disease. From the dialysis registry and medical record, then continued with follow up the subjects. Living subjects was given informed consent to perform a structured interview. The subjects who died and hard to contact, data were collect from medical record. Bivariate analysis was done using Chi-square methods, Fisher method is used as alternative. Significant variables will be further analyzed with logistic regression test. Results. From 210 subjects who undergo dialysis at the first time in Cipto Mangunkusumo Hospital, 189 patients were referred late (proportion 90%; 95% CI 86.2-93.7). From multivariate analysis, two main factors related to later referral were the assisted-ambulatory status (p=0.002; OR 6.71; 95% CI 2.02-22,32) and non-compliance (p=0.001; OR 7.42; IK 95% 2.33-23.62). Conclusions. The proportion of late referral of CKD-ESRD patients at Dr.Cipto Mangunkusumo General Hospital is 90%. Assisted-ambulatory status and non-compliance are related to late referral of CKD-ESRD patients. Further study is needed to know the role of other factors such as health care system and its implementation by physician.